1193387-98-2

Upstream product

• 369-34-6 3,4-difluoronitrobenzene 
• 1438407-67-0 2-(2-fluoro-4-nitrophenylthio) ethanamine 
• 21762-74-3 6-nitro-3,4-dihydro-3-oxo-2H(1,4)benzothiazine 
• 1202773-84-9 2-(2-iodoethylthio)-5-nitroaniline 

Downstream Products

• 1202773-87-2 2-chloro-1-(6-nitro-2H-benzo[b][1,4]thiazin-4(3H)-yl)ethanone 
• 1438407-68-1 (6-nitro-2H-benzo[b][1,4]thiazin-4(3H)-yl)(phenyl)methanone 
• 1438407-78-3 6-nitro-4-(phenylsulfonyl)-3,4-dihydro-2H-benzo[b][1,4]thiazine 
• 1438407-81-8 6-nitro-4-tosyl-3,4-dihydro-2H-benzo[b][1,4]thiazine 
• 1438405-61-8 N-(4-benzoyl-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-yl)-5-(piperidin-1-yl)pentanamide 
• 1438405-67-4 4-(phenylsulfonyl)-6-(3-(piperidin-1-yl)propoxy)-3,4-dihydro-2H-benzo[b][1,4]thiazine 
• 1438405-82-3 phenyl (6-(3-(piperidin-1-yl)propoxy)-2H-benzo[b][1,4]thiazin-4(3H)-yl)methanone 
• 1438407-87-4 4-(naphthalen-2-ylsulfonyl)-N-(3-(4-tosylpiperazin-1-yl)propyl)-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-amine 
• 1438406-49-5 N-(4-(naphthalen-2-ylsulfonyl)-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-yl)-3-(4-tosylpiperazin-1-yl)propanamide 
• 1438407-83-0 4-tosyl-N-(3-(4-tosylpiperazin-1-yl)propyl)-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-amine 
• 1438406-48-4 N-(4-tosyl-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-yl)-3-(4-tosylpiperazin-1-yl)propanamide 
• 1438407-82-9 3-chloro-N-(4-tosyl-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-yl)propanamide 
• 1184775-45-8 4-tosyl-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-amine 
• 1438407-80-7 4-(phenylsulfonyl)-N-(3-(4-tosylpiperazin-1-yl)propyl)-3,4-dihydro-2H-benzo[b][1,4]thiazin-6-amine 

Relevant academic research and scientific papers

BENZOTHIAZINE COMPOUNDS AS H3 RECEPTOR LIGANDS

The present invention provides benzothiazine derivative of formula (I), useful in the treatment of CNS disorders including cognitive disorders, ADHD, narcolepsy, pain, dementias, schizophrenia as well as obesity and sleep disorders. Pharmacological profile of these compounds includes high affinity binding with H3 receptor along with favourable selectivity profile for other aminergic receptors. The present invention also includes 'their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY

The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inh